Main Track |
|
Time |
Topic |
Speaker |
Title |
|
08:00 – 09:00 |
Registration & Networking |
|
09:00 – 09:10 |
Welcome Speech |
Sebastian Bather |
General Manager, Veeva Asia |
|
09:10 – 09:20 |
Veeva CEO Keynote |
Peter Gassner |
Veeva Founder and CEO |
|
09:20 – 09:45 |
Product Strategy in China for China |
Yue Jin |
GM, Veeva China Commercial Products |
|
09:45 – 10:10 |
Pave the Way to Pharma Digital Marketing Excellence |
Shon Gao |
Market Owner, Veeva China MNC Market |
|
10:10 – 10:35 |
Break & Networking |
|
|
|
10:35 – 11:05 |
Customer Sharing |
Wang Nan |
Information Technology VP, MSD China |
|
11:05 – 11:35 |
Commercial Innovation of Innovative Pharmaceutical Companies |
Joanthan Zhu |
Chief Commercial Operations Officer, Suzhou Yasheng Pharmaceutical |
|
11:35 – 12:05 |
Partner Sharing |
Lu Hao |
Industry General Manager, WeCom of Tencent WXG |
|
12:05 – 13:50 |
Luncheon |
|
|
|
13:50 – 14:40 |
Panel Discussion |
Moderator: David Li |
Director, Veeva China Domestic Market |
Zhao Jing |
Vice President, Medical and Marketing, TaslyBio |
Xuefeng Yin |
Director of Sales Force Effectivess, Allist |
Cheng Wang |
Head of Field Excellence, Novartis |
Jason Chen |
General Manager of IT & Digital, FUSUN |
Allan Li |
China BTS Head, Abbvie |
Nina Qu |
VP of People& Comms and SFE, Lundbeck China |
|
14:40 – 15:10 |
Trends in customer master data management in life science industry |
Monk Zhao |
Director, OpenData Product, Veeva China |
|
15:10 – 15:50 |
Break & Networking |
|
|
|
15:50 – 16:20 |
Customer Sharing |
Chron Kang |
Head of Go-To-Market Transformation, Sanofi |
|
16:20- 16:50 |
Customer Sharing |
|
|
|
16:50 – 17:40 |
Panel Discussion |
Moderator:Roger Liu |
VP and CMO, AZ China |
Is there a solution to the ‘involution’ of innovative pharmaceutical companies?
|
1. How to build effective differentiated advantages when innovative drugs pile up and the competition is fierce? |
2.”Dilemma” on innovative drugs being included in the national medical insurance catalog |
3. How to break the dilemma of innovative drug coverage and access? |
|
|